Among the top scoring hits in our Prestwick library screens (Dataset EV1, Appendix Fig S1), we identified chlorambucil, a bifunctional alkylating agent used in the past for the treatment of breast and ovarian cancer (Williams et al, 1985; Senn et al, 1997), irinotecan, a topoisomerase I inhibitor in use for the treatment of cancer patients with BRCA1 mutations (Kennedy et al, 2004), and disulfiram, an aldehyde dehydrogenase inhibitor used in the clinic as an alcohol deterrent. Here, BRCA1 is linked to ovarian carcinoma.